ibl-references

References for Gd-IgA1 (Galactose-deficient IgA1) ELISA kit and Antibody (KM55)

This list is for the purpose of introducing references that use our products.
References may be added to the list in the future.

ELISA Antibody

keyword	title	author	published	spiecies	specimen	item
Gut microbiome, Mucosal barrier, Inflammation, Local immune responses	Aberrant Gut Microbiome Contributes to Barrier Dysfunction, Inflammation, and Local Immune Responses in IgA Nephropathy.	Tang Y et al.	01Mar 6, 2023	Human	Plasma, urine	Antibody
Oral cavity, Cnm-positive Streptococcus mutans	cnm-positive Streptococcus mutans is associated with galactose-deficient IgA in patients with IgA nephropathy.	Misaki T et al.	02Mar 2, 2023	Human	Plasma	ELISA, Antibody
Disease Activity, Progression	Serum levels of galactose-deficient IgA are elevated in patients with IgA nephropathy but do not correlate to disease activity or progression.	Sigridur Eliasdottir et al.	03Jan 25, 2023	Human	Serum, urine	ELISA
O-glycan, N-acetylgalactosamine, IgA1 hinge region	Racial heterogeneity of IgA1 hinge-region O-glycoforms in patients with IgA nephropathy.	Ohyama Y et al.	04Sep 27, 2022	Human	Serum	ELISA
Zonulin	Zonulin, as a marker of intestinal permeability, is elevated in IgA nephropathy and IgA vasculitis with nephritis.	Li Q et al.	05Sep 20, 2022	Human	EDTA plasma	ELISA
Factor Ba/C5a, Oxford Pathology Classification of IgA Nephropathy	Associations between Biomarkers of Complement Activation, Galactose-Deficient IgA1 Antibody and the Updated Oxford Pathology Classification of IgA Nephropathy.	Juan YT et al.	06Jul 21, 2022	Human	Plasma	ELISA
Urinary Gd-IgA1	Galactose-Deficient IgA1 as a Candidate Urinary Marker of IgA Nephropathy.	Fukao Y et al.	07Jun 2, 2022	Human	Serum, urine	Antibody
APRIL, VIS649	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers	Mathur M et al.	08Feb 8, 2022	Human	Serum	ELISA
Sialylated IgG	Sialylation of IgG inhibits the formation of galactose-deficient IgA1-containing immune complexes and protects mesangial cells from injury in IgA nephropathy.	Liu Y et al.	09Jan 11, 2022	Human	Cell supernatants of PBMCs	ELISA
TNFR1, IgAVN, Children	Relationship between Gd-IgA1 and TNFR1 in IgA nephropathy and IgA vasculitis nephritis in children – multicenter study.	Mizerska-Wasiak M et al.	10Aug 7, 2021	Human	Serum	ELISA
APRIL	Measurement of galactosyl-deficient IgA1 by the monoclonal antibody KM55 contributes to predicting patients with IgA nephropathy with high risk of long-term progression.	Martín-Penagos L et al.	11Jul 28, 2021	Human	Serum	ELISA
Complement C5a, Factor Ba	Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA1 Antibody in IgA Nephropathy Patients.	Chiu YL et al.	12Jun 10, 2021	Human	Plasma	ELISA
Recurrent glomerulonephritis, kidney transplantation	Clinical significance of serum galactose-deficient immunoglobulin A1 for detection of recurrent immunoglobulin A nephropathy in kidney transplant recipients. Kidney Res Clin Pract.	Park WY et al.	13Apr 15, 2021	Human	Serum	ELISA
Membranous-like glomerulonephritis, Primary Sjögren’s syndrome	Glomerulonephritis with severe nephrotic syndrome induced by immune complexes composed of galactose-deficient IgA1 in primary Sjögren's syndrome: a case report.	Nishioka R et al.	14Mar 25, 2021	Human	IHC	Antibody
Alport syndrome	Utility of glomerular Gd-IgA1 staining for indistinguishable cases of IgA nephropathy or Alport syndrome.	Ishiko S et al.	15Mar 20, 2021	Human	IHC	Antibody
IgA-dominant infection-related glomerulonephritis	KM55 Monoclonal Antibody Staining in IgA-Dominant Infection-Related Glomerulonephritis.	Zhang M et al.	16Feb 17, 2021	Human	IHC	Antibody
Clinical Relevance	Clinical Relevance of Serum Galactose Deficient IgA1 in Patients with IgA Nephropathy.	Kim JS et al.	17Nov 4, 2020	Human	Serum	ELISA
Tonsillectomy (TE), Mesangial Gd-IgA1 immunoreactivity	Association Between Galactose-Deficient IgA1 Derived From the Tonsils and Recurrence of IgA Nephropathy in Patients Who Underwent Kidney Transplantation.	Kawabe M et al.	18Sep 3, 2020	Human	Serum, IF	ELISA, Antibody
Pediatric, Glomerular Diseases	Glomerular galactose-deficient IgA1 expression analysis in pediatric patients with glomerular diseases.	Ishiko S et al.	19Aug 20, 2020	Human	IF	Antibody
TLR7	TLR7 in B cells promotes renal inflammation and Gd-IgA1 synthesis in IgA nephropathy.	Zheng N et al.	20Jul 23, 2020	Human	Supernatant collected from EBV-immortalized B cells	ELISA
ST6Gal1, C1GalT1	ST6Gal1 is up-regulated and associated with aberrant IgA1 glycosylation in IgA nephropathy: An integrated analysis of the transcriptome.	Liu Y et al.	21Jul 17, 2020	Human	Plasma, cell culture supernatant	ELISA
Helicobacter pylori	Helicobacter pylori infection is associated with elevated galactose-deficient IgA1 in IgA nephropathy.	Liu XZ et al.	22Jun 11, 2020	Human	Plasma	ELISA
Children	Clinical Significance of Serum Galactose-Deficient IgA1 Level in Children with IgA Nephropathy.	Irabu H et al.	23May 21, 2020	Human	Serum	ELISA
Henoch-Schönlein purpura nephritis	A cross-sectional analysis of clinicopathologic similarities and differences between Henoch-Schönlein purpura nephritis and IgA nephropathy.	Sugiyama M et al.	24Apr 23, 2020	Human	Serum, IHC	ELISA, Antibody
C1GALT1	C1GALT1 expression is associated with galactosylation of IgA1 in peripheral B lymphocyte in immunoglobulin a nephropathy.	Xing Y et al.	25Jan 15, 2020	Human	Plasma	ELISA
Secondary IgA Nephropathy	Secondary IgA Nephropathy Shares the Same Immune Features With Primary IgA Nephropathy.	Wang M et al.	26Nov 6, 2019	Human	IF	Antibody
Uric acid, Total IgA levels, Complement activation products	Clinical Significance of Galactose-Deficient IgA1 by KM55 in Patients with IgA Nephropathy.	Zhang K et al.	27Oct 1, 2019	Human	Plasma, IHC	ELISA, Antibody
APRIL, IL-6, TLR9	TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy.	Makita Y et al.	28Sep 5, 2019	ddy mouse	Serum	Antibody
Biomarker, Serum galactose deficient IgA1	Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: A case control study.	Bagchi S et al.	29May 27, 2019	Human	Serum	ELISA
IgA vasculitis, systemic form, skin-limited form, Henoch-Schönlein purpura	Galactose-deficient IgA1 in skin and serum from patients with skin-limited and systemic IgA vasculitis.	Neufeld M et al.	30Mar 19, 2019	Human	IHC	Antibody
PST(GalNAc)PP	Galactose-Deficient IgA1-Specific Antibody Recognizes GalNAc-Modified Unique Epitope on Hinge Region of IgA1.	Yamasaki K et al.	31Dec 28, 2018	-	synthetic peptide	Antibody
Henoch-Schönlein purpura nephritis (HSPN), lupus nephritis (LN), ANCA-associated vasculitis (AAV), minimal change disease (MCD)	Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy.	Wada Y et al.	32Nov 2, 2018	Human	Serum, IHC	ELISA, Antibody
IgA nephropathy, Galactose-deficient IgA1, Immune complexes, Biomarker	Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis.	Suzuki H.	33Jan 9, 2018	Human	Serum	Antibody
IgA vasculitis, renal biopsy	IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis.	Suzuki H et al.	34Jan 9, 2018	Human	IF	Antibody
ELISA, galactose-deficient IgA1, IgA nephropathy	Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy.	Yasutake J et al.	35Jun 23, 2015	Human	Serum, IF	Antibody